|MDACC Study No:||2011-0192 (clinicaltrials.gov NCT No: NCT01440582)|
|Title:||Phase I/Ib Trial of the Efficacy and Safety of combination therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in transplant eligible patients with newly diagnosed Multiple Myeloma|
|Principal Investigator:||Jatin J. Shah|
|Treatment Agent:||Acyclovir; Aspirin; Bortezomib; Dexamethasone; Lenalidomide; Panobinostat|
|Study Description:||The goal of this clinical research study is to find the highest tolerable dose |
of the drug panobinostat that can be given in combination with the drugs
Velcade (bortezomib), Revlimid (lenalidomide), and Decadron (dexamethasone) to
patients with MM. The safety of this drug combination will also be studied.
Panobinostat is designed to cause chemical changes in different groups of
proteins that are attached to DNA (the genetic material of cells), which may
slow the growth of cancer cells or cause the cancer cells to die.
Bortezomib is designed to block a protein that causes cells to grow. This may
cause cancer cells to die.
Lenalidomide is designed to change the body's immune system. It may also
interfere with the development of tiny blood vessels that help support tumor
growth. This may slow the growth of cancer cells.
Dexamethasone is a corticosteroid that is similar to a natural hormone made by
your body. Dexamethasone is often given to MM patients in combination with
other chemotherapy to treat cancer.